Oral potassium arsenite used to be an important antileukemic agent[1][1] until the 1950s, when it was surpassed by modern chemo-therapeutic drugs. The use of arsenic resurged when its high efficacy was shown in acute promyelocytic leukemia (APL).[2][2],[3][3] However, to date, only intravenous As2O3
No takes yet. Share an insight, caveat, or question.
Au et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: